ISPOR Europe 2015: Are Spain And US The Ones To Watch For MEAs?
This article was originally published in Scrip
Despite the challenges with the implementation of managed entry agreements, the debate involving these complex market access routes is not abating. Speakers at the International Society for Pharmacoeconomics and Outcomes Research Europe meeting in Milan on 7–11 November 2015 discussed current experiences with such agreements across Europe, as they are about to make a bigger showing across the Atlantic.
You may also be interested in...
Including the impact on hospitalizations in the label for Novartis's heart failure drug Entresto was critical to enable execution of outcome-based agreements. Such deals present an opportunity for pharma and payers to work together, but many challenges remain.
Four years after its introduction, Germany's early benefit assessment process continues to make waves in the industry.
Early scientific advice from health technology assessment bodies is increasingly used by manufacturers to ensure their development programs and submission dossiers satisfy the requirements. Although the HTA bodies' advice is proving to be valuable to drug developers, further changes are needed to optimize the effectiveness of these new and evolving processes, as discussed at the eyeforpharma Market Access and Pricing Excellence event in Amsterdam on 3-4 June 2015.